Better safety and quality of life in patients with chronic hepatitis B than in patients with chronic hepatitis C when treated with peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy

被引：0
|
作者：
Marcellin, P
Lau, G
Piratvisuth, T
Luo, KX
Bonino, F
Thongasawat, S
Cooksley, G
Hadziyannis, S
Chutaputti, A
Lu, ZM
Fried, M
Chow, WC
Yurdaydin, C
Berg, T
Pluck, N
机构：
[1] Hop Beaujon, Clichy, France
[2] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[3] Songklanakarin Hosp, Songkhla, Thailand
[4] Nangfang Hosp, Guangzhou, Peoples R China
[5] IRCCS Osped Maggiore, Sci Direct, Milan, Italy
[6] Chiang Mai Univ, Chiang Mai 50000, Thailand
[7] Univ Queensland, Royal Brisbane Hosp, Herston, Qld, Australia
[8] H Dynant Hosp, Athens, Greece
[9] Pramongkutklao Hosp, Bangkok, Thailand
[10] Ruijin Hosp, Shanghai, Peoples R China
[11] Univ N Carolina, Chapel Hill, NC USA
[12] Singapore Gen Hosp, Singapore 0316, Singapore
[13] Ankara Univ, TR-06100 Ankara, Turkey
[14] Charite Humboldt Univ Berlin, Berlin, Germany
[15] Roche, Welwyn Garden City, England
来源：
HEPATOLOGY | 2004年 / 40卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：668A / 668A
页数：1
相关论文
共 50 条
  • [41] Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis
    Bruno, Savino
    Shiffman, Mitchell L.
    Roberts, Stuart K.
    Gane, Edward J.
    Messinger, Diethelm
    Hadziyannis, Stephanos J.
    Marcellin, Patrick
    HEPATOLOGY, 2010, 51 (02) : 388 - 397
  • [42] Efficacy and safety of 22 weeks of maintenance therapy with Peginterferon alfa-2a (40KD) (PEGASYS™) alone versus Peginterferon alfa-2a (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of Peginterferon alfa-2a (40KD) plus ribavirin:: An open, multicenter, randomized trial.
    Bronowicki, JP
    Ouzan, D
    Tzanck, A
    Asselah, T
    Desmorat, H
    Zarski, JP
    Foucher, J
    Bourliere, M
    Renou, C
    Tran, A
    Melin, P
    Hezode, C
    Chevallier, M
    Bouvier, M
    Lonjon-Domanec, I
    Pawlotsky, JM
    HEPATOLOGY, 2003, 38 (04) : 244A - 245A
  • [43] Effect of hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 treated with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 or 24 weeks
    Rodriguez-Torres, Maribel
    Govindarajan, Sugantha
    Shafran, Stephen
    Morgan, Timothy
    Anand, Bhupinder S.
    Barange, Karl
    Suter, Fredy
    Lin, Amy
    Hooper, Gregory
    Zeuzem, Stefan
    Shiffman, Mitchell
    HEPATOLOGY, 2006, 44 (04) : 333A - 333A
  • [44] Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy for HBEAG-negative chronic hepatitis B
    Marcellin, P
    Bonino, F
    Lau, GY
    Farci, P
    Yurdaydin, C
    Piratvisuth, T
    Jin, R
    Gurel, S
    Hadziyannis, S
    Lu, ZM
    Popescu, M
    HEPATOLOGY, 2005, 42 (04) : 580A - 580A
  • [45] Peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B:: Results from a large, multinational study.
    Lau, G
    Piratvisuth, T
    Luo, KX
    Marcellin, P
    Thongasawat, S
    Cooksley, G
    Gane, E
    Fried, M
    Chow, WC
    Paik, SW
    Chang, WY
    Berg, T
    Flisiak, R
    Zahm, F
    Pluck, N
    HEPATOLOGY, 2004, 40 (04) : 171A - 171A
  • [46] PEG-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C
    Ideo, G
    Giuseppe, S
    Attili, A
    Chirianni, A
    Craxi, A
    Di Perri, G
    Picciotto, A
    Rizzetto, M
    Ruggiero, G
    Suter, F
    Sarracino, M
    HEPATOLOGY, 2002, 36 (04) : 570A - 570A
  • [47] Efficacy and tolerability of peginterferon alfa-2a (40kd) and ribavirin in genotype 4 patients with chronic hepatitis C (CHC) under real life conditions
    Zehnter, E.
    Mauss, S.
    Kaiser, S.
    Boeker, K.
    Lutz, T.
    Heyne, R.
    John, C.
    Moog, G.
    Schober, A.
    Pfaff, R.
    Zipf, A.
    Racky, S.
    Lohmeyer, J.
    Bokemeyer, B.
    Kallinowski, B.
    Witthoeft, T.
    Alshuth, U.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S316 - S316
  • [48] Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
    Heathcote, EJ
    Shiffman, ML
    Cooksley, WGE
    Dusheiko, GM
    Lee, SS
    Balart, L
    Reindollar, R
    Reddy, RK
    Wright, TL
    Lin, A
    Hoffman, J
    De Pamphilis, J
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (23): : 1673 - 1680
  • [49] Efficacy and safety of peginterferon alfa-2a (40KD) and ribavirin in Gt-2/3patients with chronic hepatitis C in a real world setting
    Zehnter, Elmar
    Mauss, Stefan
    John, Christine
    Heyne, Renate
    Moeller, Bernd
    Lutz, Thomas
    Bokemeyer, Bernd
    Kihn, Robert
    Moog, Gero
    Vornkahl, Heike
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2006, 130 (04) : A841 - A841
  • [50] Cost-effectiveness of peginterferon alfa-2a (40KD) (PEGASYS®) compared to lamivudine as first line treatment of chronic hepatitis B (CHB) in the UK
    Veenstra, DL
    Sullivan, SD
    Dusheiko, GM
    Jacobs, M
    Lewis, GJ
    Patel, KK
    VALUE IN HEALTH, 2005, 8 (06) : A120 - A120
12345